GlobeNewsWire
15 Jul 2026, 02:41 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a class action securities lawsuit alleging the use of channel stuffing to artificially inflate revenue. — Allegations of revenue manipulation via channel stuffing strike at the core of financial integrity and usually lead to significant stock price corrections.
-0.60The lawsuit alleges that ADMA Biologics failed to disclose material information regarding related party transactions and lacked adequate internal controls. — Poor internal controls and undisclosed related party transactions suggest governance failures and potential further accounting irregularities.
-0.40The class action seeks to recover losses for investors who purchased ADMA securities between August 9, 2024, and March 25, 2026. — Defines the scope of potential liability and the group of affected shareholders, though the legal outcome is still pending.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is the subject of a securities fraud lawsuit.
The company is facing a class action securities lawsuit alleging corporate fraud, channel stuffing, and lack of internal controls.
The company is facing securities litigation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
